Indian Researchers Develop Targeted Nano-Formulation to Aid Parkinson’s Disease Management

Mohali: In a groundbreaking advancement, researchers from the Institute of Nano Science and Technology (INST), Mohali, have developed a targeted nano-formulation that enables the sustained release of 17β-Estradiol (E2), a hormone critical for managing Parkinson’s Disease (PD). This innovation holds promise for revolutionizing treatment strategies for the debilitating neurodegenerative condition.

Parkinson’s Disease, a progressive neurological disorder, is often linked to an imbalance of 17β-Estradiol in the brain. While the hormone’s neurotherapeutic potential is well-known, its use in PD treatment has been limited by peripheral side effects and a lack of comprehensive understanding of its molecular mechanisms.

To address these challenges, scientists at INST, an autonomous institute under the Department of Science and Technology (DST), designed a novel nano-formulation. The research involves dopamine receptor D3 (DRD3) conjugated to chitosan nanoparticles loaded with 17β-Estradiol. This innovative system ensures a sustained release of E2 directly to the brain, significantly enhancing its efficacy while minimizing systemic side effects.

The targeted nano-formulation demonstrated remarkable neuroprotective capabilities by inhibiting mitochondrial translocation of calpain, a protease known to cause neuronal damage. By mitigating rotenone-induced mitochondrial damage, the formulation helped preserve neuronal integrity.

Moreover, the study uncovered a novel molecular insight: the BMI1 protein, part of the PRC1 complex responsible for regulating mitochondrial homeostasis, is a substrate of calpain. The nano-formulation restored BMI1 expression by preventing its degradation, thus maintaining mitochondrial balance—a critical factor in mitigating Parkinson’s symptoms.

The efficacy of the nano-formulation was validated in rodent models, where it alleviated behavioral impairments associated with PD. Published in the journal Carbohydrate Polymers, the study also highlights the hormone’s role in reducing oxidative stress, a key contributor to PD progression.

While this breakthrough offers hope for Parkinson’s patients, researchers emphasize the need for further exploration of long-term safety profiles and enhanced delivery systems to ensure the widespread applicability of the drug.

“This innovation not only sheds light on the molecular mechanisms underlying Parkinson’s Disease but also offers a safer and more effective approach to therapy. With further refinement, it has the potential to improve the quality of life for millions of PD patients worldwide,” said a spokesperson from INST.

The development of this targeted nano-formulation marks a significant stride in Parkinson’s research, showcasing India’s growing prowess in advanced medical and nanotechnology solutions. By addressing key challenges in PD treatment, this innovation opens new avenues for combating neurodegenerative disorders, offering renewed hope to patients and their families.